Eli Lil­ly's Covid-19 part­ner Ab­Cellera pays $90M for some very spe­cial mice as Pe­ter Thiel jumps on the board and IPO ru­mors heat up

Ab­Cellera Bi­o­log­ics is step­ping on­to Re­gen­eron’s turf, putting down $90 mil­lion in cash to buy out Tri­an­ni and its hu­man­ized mouse tech­nol­o­gy for de­vel­op­ing an­ti­bod­ies.

The 7-year-old biotech out of British Co­lum­bia is af­ter the Tri­an­ni Mouse: a ge­net­i­cal­ly en­gi­neered ro­dent that can gen­er­ate ful­ly hu­man mon­o­clon­al an­ti­bod­ies. It’s al­so scoop­ing up sev­er­al “next-gen­er­a­tion” mice un­der de­vel­op­ment. The move comes as Ab­Cellera preps one of the biggest IPOs in an al­ready record-break­ing year for pub­lic de­buts, un­named sources told Bloomberg. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.